Protagonist Therapeutics, Inc Operating Lease Cost
Protagonist Therapeutics, Inc (PTGX) reported Operating Lease Cost of $2.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-25
- Protagonist Therapeutics, Inc operating lease, cost for the quarter ending 2024-12-31 was $380.00K, a 34.93% decline year-over-year.
- Protagonist Therapeutics, Inc operating lease, cost for the quarter ending 2024-09-30 was $757.00K, a 29.62% increase year-over-year.
- Protagonist Therapeutics, Inc operating lease, cost for the quarter ending 2024-06-30 was $738.00K, a 26.37% increase year-over-year.
- Protagonist Therapeutics, Inc operating lease, cost for the quarter ending 2023-12-31 was $584.00K.
- Protagonist Therapeutics, Inc operating lease, cost for fiscal 2025 was $2.31M, a 6.14% decline from fiscal 2024.
- Protagonist Therapeutics, Inc operating lease, cost for fiscal 2024 was $2.46M, a 5.31% increase from fiscal 2023.
- Protagonist Therapeutics, Inc operating lease, cost for fiscal 2023 was $2.33M, a 0.00% change from fiscal 2022.
- Protagonist Therapeutics, Inc operating lease, cost for fiscal 2022 was $2.33M, a 19.01% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.31M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.14M derived: sum of 2 quarters · filed 2026-02-25 | $1.88M derived: sum of 3 quarters · filed 2026-02-25 | $2.46M 10-K · filed 2026-02-25 |
| 2024-09-30 | $757.00K 10-Q · filed 2024-11-07 | $1.50M derived: sum of 2 quarters · filed 2024-11-07 | $2.08M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $738.00K 10-Q · filed 2024-08-06 | $1.32M 10-Q · filed 2024-08-06 | ||
| 2023-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.17M derived: sum of 2 quarters · filed 2026-02-25 | $1.75M derived: sum of 3 quarters · filed 2026-02-25 | $2.33M 10-K · filed 2026-02-25 |
| 2023-09-30 | $584.00K 10-Q · filed 2024-11-07 | $1.17M derived: sum of 2 quarters · filed 2024-11-07 | $1.75M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $584.00K 10-Q · filed 2024-08-06 | $1.17M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $2.33M 10-K · filed 2025-02-21 | |||
| 2021-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.96M 10-K · filed 2024-02-27 | ||
| 2021-09-30 | $1.38M 10-Q · filed 2021-11-03 | |||
| 2020-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.77M 10-K · filed 2023-03-15 | ||
| 2020-09-30 | $1.33M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $889.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.33M derived: sum of 3 quarters · filed 2022-02-28 | $1.79M 10-K · filed 2022-02-28 |
| 2019-09-30 | $444.00K 10-Q · filed 2019-11-06 | $888.00K derived: sum of 2 quarters · filed 2019-11-06 | $1.35M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $444.00K 10-Q · filed 2019-08-07 | $903.00K 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $459.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |